Oppenheimer & Co. Inc. Buys 10,647 Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Oppenheimer & Co. Inc. boosted its position in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 44.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 34,407 shares of the specialty pharmaceutical company’s stock after buying an additional 10,647 shares during the period. Oppenheimer & Co. Inc.’s holdings in Valeant Pharmaceuticals International were worth $379,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Valeant Pharmaceuticals International by 9.8% in the first quarter. Vanguard Group Inc. now owns 6,980,074 shares of the specialty pharmaceutical company’s stock valued at $76,990,000 after buying an additional 621,618 shares during the period. OppenheimerFunds Inc. boosted its position in shares of Valeant Pharmaceuticals International by 17.1% in the first quarter. OppenheimerFunds Inc. now owns 4,489,169 shares of the specialty pharmaceutical company’s stock valued at $49,516,000 after buying an additional 656,116 shares during the period. Morgan Stanley boosted its position in shares of Valeant Pharmaceuticals International by 48.2% in the first quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock valued at $30,631,000 after buying an additional 903,256 shares during the period. Norges Bank acquired a new position in shares of Valeant Pharmaceuticals International during the fourth quarter valued at $39,286,000. Finally, Legal & General Group Plc boosted its position in shares of Valeant Pharmaceuticals International by 6.0% in the first quarter. Legal & General Group Plc now owns 1,314,638 shares of the specialty pharmaceutical company’s stock valued at $14,481,000 after buying an additional 74,193 shares during the period. Institutional investors own 50.42% of the company’s stock.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) traded down 1.69% during trading on Friday, reaching $16.84. The company’s stock had a trading volume of 12,242,293 shares. Valeant Pharmaceuticals International, Inc. has a 1-year low of $8.31 and a 1-year high of $32.74. The stock has a 50 day moving average price of $15.93 and a 200 day moving average price of $13.36. The stock’s market capitalization is $5.86 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.93. The company had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.17 billion. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. Valeant Pharmaceuticals International’s revenue for the quarter was down 11.1% compared to the same quarter last year. During the same quarter last year, the company earned ($1.08) EPS. Analysts anticipate that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current fiscal year.

WARNING: “Oppenheimer & Co. Inc. Buys 10,647 Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX)” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/07/28/valeant-pharmaceuticals-international-inc-nysevrx-shares-bought-by-oppenheimer-co-inc-updated-updated-updated.html.

VRX has been the subject of several analyst reports. Jefferies Group LLC set a $18.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “buy” rating in a report on Saturday, May 6th. Guggenheim initiated coverage on shares of Valeant Pharmaceuticals International in a report on Saturday, June 17th. They issued a “buy” rating and a $18.00 target price for the company. Mizuho reissued an “underperform” rating and issued a $8.00 target price on shares of Valeant Pharmaceuticals International in a report on Tuesday, June 20th. BMO Capital Markets reissued a “hold” rating and issued a $15.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday. Finally, Zacks Investment Research raised shares of Valeant Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Thursday. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $16.81.

In related news, Director Schutter Richard U. De purchased 20,000 shares of Valeant Pharmaceuticals International stock in a transaction on Thursday, May 11th. The shares were bought at an average price of $13.90 per share, with a total value of $278,000.00. Following the transaction, the director now directly owns 70,572 shares of the company’s stock, valued at $980,950.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.87% of the stock is owned by company insiders.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply